Filing Details

Accession Number:
0000899243-16-017729
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-04-06 17:02:43
Reporting Period:
2016-04-05
Filing Date:
2016-04-06
Accepted Time:
2016-04-06 17:02:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
907654 Arca Biopharma Inc. ABIO In Vitro & In Vivo Diagnostic Substances (2835) 363855489
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1266125 R Michael Bristow Arca Biopharma, Inc.
11080 Circlepoint Road, Suite 140
Westminster CO 80020
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-04-05 724 $3.52 44,610 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 19,986 Indirect By Investocor Trust as sole Trustee
Common Stock 25,459 Indirect By NFS Custodian for Michael Bristow's IRA
Footnotes
  1. Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").
  2. Includes (i) remaining 5,952 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 30,027 previously reported shares of common stock held directly.
  3. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $3.52 to $3.524. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.